文献速递帕金森病与运动障碍认知障碍与痴呆

NOTCH2NLC重复扩增与帕金森病的关联

Association of NOTCH2NLC Repeat Expansions With Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项病例对照研究在新加坡两家三级运动障碍中心纳入1000例散发性帕金森病患者和1076名健康对照,采用PCR筛查NOTCH2NLC GGC重复扩增。结果显示13例患者携带超过40次重复,频率显著高于对照(P < .001),其中部分患者表现为典型帕金森病且对低剂量左旋多巴反应良好,无NIID临床或影像特征。

要点

  • 散发性帕金森病患者中可检出NOTCH2NLC GGC重复扩增,频率高于健康对照。
  • 携带扩增的患者可表现为典型帕金森病,对低剂量左旋多巴反应良好,无NIID特征。
  • 患者扩增序列中无GGA中断,AGC中断频率高于NIID患者。

核心结论

  • 携带致病性NOTCH2NLC GGC重复扩增的散发性帕金森病患者可表现为典型帕金森病,仅需低剂量左旋多巴,随访多年无NIID临床或影像特征。

研究设计与样本

  • 病例对照研究,在新加坡2家三级运动障碍中心招募2005年1月至2020年1月的参与者。
  • 共2076名参与者,包括1000例散发性帕金森病(600名男性,占60.0%;平均发病年龄62.6岁,SD 7.7)和1076名健康对照(581名男性,占54.0%;研究招募时平均年龄54.9岁,SD 9.4)。
  • 采用聚合酶链反应检测NOTCH2NLC GGC扩增重复,代表性样本用长读长基因组测序验证。

主要发现

  • 13例帕金森病患者和0名健康对照携带超过40个单位的NOTCH2NLC GGC重复扩增,患者频率高于对照(P < .001)。
  • 10例帕金森病患者携带41至64次GGC扩增(占散发性帕金森病的1%;平均49.4次,SD 9.2)。
  • 3例患者携带79个或以上GGC重复,其中2例分别有122和79次重复,表现为典型帕金森病并对小剂量左旋多巴多年反应良好,无NIID临床或影像特征;另1例有130次重复,死亡前仅出现认知障碍。
  • 在GGC扩增内,3例帕金森病患者无GGA中断(平均0%),而NIID患者平均为12%(SD 9%);帕金森病患者AGC中断频率是NIID患者的3倍(平均25%,SD 12% vs 8%,SD 8%)。

临床怎么用

  • 对散发性帕金森病患者可考虑NOTCH2NLC GGC重复扩增筛查,尤其表现为典型帕金森病且对低剂量左旋多巴反应良好者。
  • 携带NOTCH2NLC扩增的帕金森病患者可能长期不出现NIID特征,管理可参照典型帕金森病。

局限性

  • 中等长度重复扩增在帕金森病患者中较健康对照更常见,其功能意义有待进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The presence of Notch homolog 2 N-terminal-like C (NOTCH2NLC) repeat expansions are associated with neuronal intranuclear inclusion body disease (NIID), with varied neurological signs, including neuropathy, ataxia, parkinsonism, and tremor. To date, genetic screening of NOTCH2NLC GGC repeats in a cohort with typical Parkinson disease (PD) appears not to have been reported. OBJECTIVE: To investigate if NOTCH2NLC GGC expansions are present in a cohort of patients with PD and controls. DESIGN, SETTING, AND PARTICIPANTS: This case-control study was conducted in 2 tertiary movement disorder centers in Singapore. Participants were recruited and followed up from January 2005 to January 2020. The presence of NOTCH2NLC GGC expansion repeats was screened using polymerase chain reaction tests, and representative samples were verified with long-read genome sequencing. MAIN OUTCOMES AND MEASURES: Qualitative and quantitative comparisons between participants with sporadic PD, healthy control participants, and individuals with NIID. RESULTS: A total of 2076 participants, including 1000 with sporadic PD (600 men [60.0%]; mean age at onset, 62.6 [7.7] years) and 1076 healthy controls (581 men [54.0%]; mean age at study recruitment, 54.9 [9.4] years) were recruited. A total of 13 patients with PD and no healthy control participants were identified as carrying NOTCH2NLC GGC repeat expansions of more than 40 units; the frequency of more than 40 repeat expansions was higher in participants with PD than controls (P < .001). None of the patients with PD were carriers of known PD-associated genes. Ten patients with PD carried a GGC expansion of between 41 and 64 repeats (1% of patients with sporadic PD; mean [SD], 49.4 [9.2] repeats). The other 3 patients carried GGC repeats of 79 or more units, 2 with 122 and 79 repeats, respectively, exhibited typical parkinsonism and were responsive to small dosages of levodopa over many years, with no clinical or imaging features of NIID. The other patient with PD, who had 130 repeats, only developed cognitive impairment before death. Within the GGC expansions, there was no GGA interruptions (mean [SD] GGA percentage in the 3 patients with PD vs patients with NIID, 0% vs 12% [9%]), and the frequency of AGC interruptions was 3 times higher in these patients with PD than patients with NIID (mean [SD], 25% [12%] vs 8% [8%]). CONCLUSIONS AND RELEVANCE: This study demonstrated that individuals with sporadic PD who carried pathogenic NOTCH2NLC GGC repeat expansions can present with typical parkinsonism, requiring only low dosages of levodopa, without displaying other clinical or imaging features of NIID even after several years of follow-up. None of the patients with PD had GGA interruptions within their GGC expansions, and the frequency of AGC interruptions was much higher than that of patients with NIID. The functional significance of a higher moderate repeat expansion in patients with PD compared with healthy controls needs to be further investigated.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Ma D, Tan YJ, Ng ASL, et al. Association of NOTCH2NLC Repeat Expansions With Parkinson Disease. JAMA Neurol. 2020. PMID: 32852534. doi:10.1001/jamaneurol.2020.3023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。